ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking.

Onweni, Chidinma L; Zhang, Yu Shrike; Caulfield, Thomas; Hopkins, Christopher E; Fairweather, De Lisa; Freeman, William D

Onweni, Chidinma L; Zhang, Yu Shrike; Caulfield, Thomas; Hopkins, Christopher E; Fairweather, De Lisa; Freeman, William D.

Onweni CL; Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL, USA.
Zhang YS; Division of Engineering in Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Caulfield T; Department of Neurologic Surgery, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA.
Hopkins CE; Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA.
Fairweather L; Brigham and Women's Hospital, Boston, MA, USA.
Freeman WD; InVivo Biosystems, Eugene, OR, USA.

Crit Care ; 24(1): 475, 2020 07 31.

Article in English | MEDLINE | ID: covidwho-690924

Subject(s)

Angiotensin Receptor Antagonists/therapeutic use; Angiotensin-Converting Enzyme Inhibitors/therapeutic use; Coronavirus Infections/drug therapy; Pneumonia, Viral/drug therapy; Angiotensin Receptor Antagonists/adverse effects; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors/adverse effects; Betacoronavirus/physiology; COVID-19; Humans; Pandemics; Peptidyl-Dipeptidase A/metabolism; SARS-CoV-2; Treatment Outcome; Virus Attachment

Keywords

ACE2; ACEI/ARB therapy; COVID-19

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Angiotensin-Converting Enzyme Inhibitors / Coronavirus Infections / Angiotensin Receptor Antagonists Type of study: Prognostic study Limits: Humans Language: English Journal: Crit Care Year: 2020 Document Type: Article Affiliation country: S13054-020-03195-9

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google